Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Proteomics has become an important field in molecular sciences, as it provides valuable
information on the identity, expression levels, and modification of proteins. For example …

Glioblastoma (GBM) is one of the most aggressive cancers of the brain. Despite extensive
research over the last several decades, the survival rates for GBM have not improved and …

In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with
limited therapeutic option and poorly understood mechanism. By studying the mutational …

Glioblastoma multiforme is the most aggressive malignant tumor of the central nervous
system. Due to the absence of effective pharmacological and surgical treatments, the …

Glioblastoma (GBM) is a highly malignant brain tumor characterized by a heterogeneous
population of genetically unstable and highly infiltrative cells that are resistant to …

Although nanomedicine have greatly developed and human life span has been extended,
we have witnessed the soared incidence of central nervous system (CNS) diseases …

Deregulated de novo lipid synthesis (DNLS) is a potential druggable vulnerability in
glioblastoma (GBM), a highly lethal and incurable cancer. Yet the molecular mechanisms …